Loading
Latest filing published 25 Apr 2025 for 派林生物, €20k.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
赵玉林 (chief executive) discloses dealings in 派林生物 to SSE / SZSE (CSRC). Over a trading history stretching from 10 September 2021 to 25 April 2025, the count stands at 3 filings.
Every open-market trade on record is a purchase: 3 purchases worth €40k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings 2 purchases and no sales.
The median purchase comes to €15k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of +6.0%, with the price up in 67% of them. These figures describe past trades and do not predict future prices.
The newest entry dates from 25 April 2025: an open-market purchase of €20k, in 派林生物. The median gap between trade and publication is zero days: most filings appear on the same day. This delay matters because a trade only becomes useful information once it is public. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations